RLYB|Rallybio Corp|Price:4.750|Chg%:0.10

More Details of Rallybio Corp Company

Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.

Rallybio Corp Info



Ticker SymbolRLYB

Company nameRallybio Corp

IPO dateJul 29, 2021

CEOUden (Stephen)

Number of employees25

Security typeOrdinary Share

Fiscal year-endJul 29

Address234 Church Street

CityNEW HAVEN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code06510

Phone12038593820

Websitehttps://rallybio.com/

Ticker SymbolRLYB

IPO dateJul 29, 2021

CEOUden (Stephen)

Company Executives of Rallybio Corp



Name

Name/Position

Position

Shareholding

Change

Dr. Stephen (Steve) Uden, M.D.

President, Chief Executive Officer, Director

91.92K

+625.00%

Ms. Paula Soteropoulos

Independent Director

2.98K

--

Mr. Jonathan I. (Jon) Lieber

Chief Financial Officer, Treasurer

2.40K

+625.00%

Dr. Steven W. Ryder, M.D.

Chief Medical Officer

--

Ms. Helen M. Boudreau

Independent Director

--

Dr. Robert (Rob) Hopfner, Ph.D.

Independent Director

--

Mr. Ronald M. (Ron) Hunt

Independent Director

--

Dr. Lucian Iancovici, M.D.

Independent Director

--

Ms. Christine A. Nash

Independent Director

--

Dr. Hui Liu, Ph.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Stephen (Steve) Uden, M.D.

President, Chief Executive Officer, Director

91.92K

+625.00%

Ms. Paula Soteropoulos

Independent Director

2.98K

--

Mr. Jonathan I. (Jon) Lieber

Chief Financial Officer, Treasurer

2.40K

+625.00%

Dr. Steven W. Ryder, M.D.

Chief Medical Officer

--

Ms. Helen M. Boudreau

Independent Director

--

Dr. Robert (Rob) Hopfner, Ph.D.

Independent Director

--

Revenue Breakdown

FY2025Q3

FY2024

By BusinessUSD

Name

Revenue

Proportion

Collaboration And License Revenue

212.00K

0.00%

Relevant data have not been disclosed by the company yet.

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Collaboration And License Revenue

212.00K

0.00%

Shareholding Stats

Updated: Tue, Nov 18

Shareholders

Shareholder Types

Shareholders

Proportion

Viking Global Investors LP

9.93%

Johnson & Johnson Innovation-JJDC, Inc.

8.61%

5AM Ventures

8.59%

New Leaf Venture Partners LLC

7.82%

TPG Capital, L.P.

7.17%

Other

57.88%

Shareholders

Proportion

Viking Global Investors LP

9.93%

Johnson & Johnson Innovation-JJDC, Inc.

8.61%

5AM Ventures

8.59%

New Leaf Venture Partners LLC

7.82%

TPG Capital, L.P.

7.17%

Other

57.88%

Shareholder Types

Shareholders

Proportion

Venture Capital

33.70%

Investment Advisor

12.07%

Investment Advisor/Hedge Fund

10.98%

Private Equity

7.17%

Individual Investor

4.12%

Hedge Fund

3.05%

Research Firm

0.14%

Pension Fund

0.03%

Other

28.74%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

137

28.34M

67.09%

-7.12M

2025Q3

138

29.20M

69.11%

-6.14M

2025Q2

146

33.40M

80.25%

-5.22M

2025Q1

153

34.13M

82.02%

-4.90M

2024Q4

156

33.77M

81.40%

-4.07M

2024Q3

163

33.31M

80.30%

-4.27M

2024Q2

165

34.52M

83.29%

-5.35M

2024Q1

149

33.11M

86.93%

-2.72M

2023Q4

143

34.47M

90.96%

-619.59K

2023Q3

138

35.89M

94.72%

-1.76M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Viking Global Investors LP

4.19M

9.93%

--

Sep 30, 2025

Johnson & Johnson Innovation-JJDC, Inc.

3.64M

8.61%

--

Sep 30, 2025

5AM Ventures

3.63M

8.59%

--

Dec 19, 2025

New Leaf Venture Partners LLC

3.30M

7.82%

--

Sep 30, 2025

TPG Capital, L.P.

3.03M

7.17%

--

Sep 30, 2025

Pivotal Bioventure Partners Investment Advisor LLC

2.40M

5.69%

--

Sep 30, 2025

Fidelity Management & Research Company LLC

1.69M

4.01%

-175.89K

-9.40%

Sep 30, 2025

Almitas Capital LLC

1.54M

3.64%

-278.76K

-15.34%

Sep 30, 2025

The Vanguard Group, Inc.

999.63K

2.37%

+89.69K

+9.86%

Sep 30, 2025

Aju IB Investment Co., Ltd.

754.68K

1.79%

--

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

Global X Russell 2000 ETF

0%

Avantis US Small Cap Equity ETF

0%

ProShares UltraPro Russell2000

0%

ProShares Hedge Replication ETF

0%

iShares Russell 2000 Value ETF

0%

Proshares Ultra Russell 2000

0%

iShares Micro-Cap ETF

0%

Global X Russell 2000 Covered Call ETF

0%

iShares Russell 2000 ETF

0%

Global X Russell 2000 ETF

Proportion0%

Avantis US Small Cap Equity ETF

Proportion0%

ProShares UltraPro Russell2000

Proportion0%

ProShares Hedge Replication ETF

Proportion0%

iShares Russell 2000 Value ETF

Proportion0%

Proshares Ultra Russell 2000

Proportion0%

iShares Micro-Cap ETF

Proportion0%

Global X Russell 2000 Covered Call ETF

Proportion0%

iShares Russell 2000 ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

Jan 29, 2026

Merger

8→1

Date

Ex-dividend Date

Type

Ratio

Jan 29, 2026

Merger

8→1